Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
10 mars 2025 16h12 HE
|
Coherus BioSciences, Inc.
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year –– LOQTORZI® net revenue increased 29%...
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
03 mars 2025 08h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be...
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
24 févr. 2025 09h08 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at...
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
22 janv. 2025 07h00 HE
|
Coherus BioSciences, Inc.
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor...
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08 janv. 2025 08h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
18 déc. 2024 08h30 HE
|
Coherus BioSciences, Inc.
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) --...
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
03 déc. 2024 07h00 HE
|
Coherus BioSciences, Inc.
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund...
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
27 nov. 2024 16h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare...
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
06 nov. 2024 16h01 HE
|
Coherus BioSciences, Inc.
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract...
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
30 oct. 2024 16h20 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after...